Journal of Diagnostics Concepts & Practice >

2022 , Vol. 21 >Issue 04: 524 - 526

DOI: https://doi.org/10.16150/j.1671-2870.2022.04.018

Case reports

Leishmaniasis with secondary hemophagocytic syndrome: a case report

Expand
  • 1. Department of Laboratory, Wuxi Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Jiangsu, Wuxi 214000, China
    2. Department of Laboratory, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-01-20

  Online published: 2022-11-07

Fold

Abstract

Leishmaniasis is an infection caused by Leishmania. Different species of Leishmania cause different clinical syndromes. Hemophagocytic syndrome (HPS) is an immune related systemic inflammatory response syndrome mediated by many factors. This paper reported that one male patient with “fever of unknown origin, connective tissue disease” who was not effectively treated and was admitted to the Wuxi District Hospital in Jiangsu Province. After the analysis of clinical manifestations and the inquiry of the working history in the western mountain area, the patient was finally diagnosed as HPS secondary to Leishmaniasis by etiological and genetic examination. The patient was treated with antimony sodium gluconate for Leishmaniasis, according to the 1994 scheme of hemophagocytic syndrome treatment (HLH-94), and was discharged after his condition improved. When HPS secondary to Leishmaniasis, the disease develops rapidly. It is not common, and is easy to miss diagnosis. This paper reports a case of a patient in the eastern plain area, which the doctors should pay more attention to in clinic.

Key words： Leishmaniasis; Hemophagocytic syndrome; Fever

Cite this article

XIONG Xinhai, LI Jia, DING Xiaosong, JI Congcong, SHI Hourong, XIANG Minjie . Leishmaniasis with secondary hemophagocytic syndrome: a case report[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 524 -526 . DOI: 10.16150/j.1671-2870.2022.04.018

References

[1] 宋瑞, 吕琳, 谭嘉禾, 等. 利什曼病合并噬血综合征1例[J]. 现代医药卫生, 2020, 36(12):1942-1944.
[1] Song R, Lv L, Tan JH, et al. Leishmaniasis complicated with hemophagocytic syndrome: a case report[J]. J Mod Med & Health, 2020, 36(12):1942-1944
[2] 张鸿娟, 黄本林, 杨雪婷, 等. 1例内脏利什曼病死亡病例诊治体会[J]. 检验医学, 2020, 35(10):1083-1086.
[2] Zhang HJ, Huang BL, Yang XT. Diagnosis and treatment experience of 1 case of visceral leishmaniasis death[J]. Lab Med, 2020, 35(10):1083-1086.
[3] 袁宏, 唐红, 张跃新. 中国利什曼原虫感染诊断和治疗专家共识[J]. 中华传染病杂志, 2017, 35(9):513-518.
[3] Yuan H, Tang H, Zhang YX. Expert consensus on diagnosis and treatment of Leishmania sinensis infection in China[J]. Chin J Infect Med, 2017, 35(9):513-518.
[4] 唐雪梅, 赵晓东. 噬血细胞综合征遗传特点与免疫发病机制[J]. 中国实用儿科杂志, 2012, 27(10):744-747.
[4] Tang XM, Zhao XD. Genetic characteristics and immune pathogenesis of hemophagocytic syndrome[J]. Chinese Journal of Practical Pediatrics, 2012, 27(10):744-747.
[5] 李红, 赵亚楠, 赵丽琴, 等. 山西省1例再发内脏利什曼病患者诊治体会[J]. 中华地方病学杂志, 2019(3):247-248.
[5] Li H, Zhao YN, Zhao LQ, et al. Diagnosis and treatment experience of a patient with recurrent visceral leishmaniasis in Shanxi Province[J]. Chinese Journal of Endemiology, 2019(3):247-248
[6] Henter JI, M Aricò, Egeler R M, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis[J]. Med Pediatr Oncol, 1997, 28(5):342-347.
[6] Henter J I, M Aricò, Egeler R M, et al. HLH-94: 噬血细胞性淋巴组织细胞增多症的治疗方案. 组织细胞学会HLH研究小组. 医学儿科杂志, 1997, 28(5):342-347.
[7] 郑玉华, 白永飞, 帖萍, 等. 2010-2019年山西省人群内脏利什曼病流行特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3):352-358.
[7] Zheng YH, Bai YF, Tie P, et al. Epidemiological characteristics of visceral leishmaniasis in shanxi population from 2010 to 2019[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2021, 39(3):352-358.
[8] 管立人, 高春花. 利什曼病及其防治[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(4):418-424,428.
[8] Guan LR, Gao CH. Leishmaniasis and its control[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2018, 36(04):418-424+428.
[9] 赵彤, 刘永清, 张健, 等. 1例输入性黑热病病例的调查[J]. 预防医学论坛, 2020, 26(1):74-75.
[9] Zhao T, Liu YQ, Zhang J, et al. Investigation of 1 case of imported kala-azar[J]. Prevent Med Tri, 2020, 26(1):74-75.
[10] 凌攀, 王晓凤, 赵仪, 等. 2015-2019年四川省疾控黑热病病例流行特征分析[J]. 解放军预防医学杂志, 2020, 38(4):63-65.
[10] Ling P, Wang XF, Zhao Y, et al. Epidemiological characteristics of disease-controlled black fever cases in Sichuan Province, 2015-2019[J]. PLA Journal of Preventive Medicine, 2020, 38(4):63-65.
[11] World Health Organization. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases[R]. Geneva, Switzerland, 2010.
[12] 中华医学会儿科学分会血液学组. 噬血细胞性淋巴组织细胞增生症诊疗建议[J]. 中华儿科杂志, 2012, 50(11):821-825.
[12] Hematology Group of Science Branch of Chinese Medical Association. Recommendations for the diagnosis and treatment of hemophagocytic lymphohistoplasia[J]. Chinese Journal of Pediatrics, 2012, 50(11): 821-825.
[13] 康艳. 骨髓检查确诊黑热病3例[J]. 临床医药文献电子杂志, 2020, 7(23):174,194.
[13] Kang Y. Bone marrow examination confirmed 3 cases of kala-azar[J]. Electronic Journal of Clinical Medical Literature, 2020, 7(23):174,194.
[14] 叶梅, 魏立. 疑难黑热病诊治1例体会并文献复习[J]. 临床医药文献电子杂志, 2020, 7(5):1,3.
[14] Ye M, Wei L. Diagnosis and treatment of difficult black fever in a case and literature review[J]. Electronic Journal of Clinical Medical Literature, 2020, 7(5):1,3.
Options
Outlines

/

〈 〉